Soliciting opinions on CIPH, now that it's starting to look interesting, price-wise.
My take is as follows. The BioSepra deal looks good to me at a bit more than 2x sales. IVGN is a big force in the market place, and this deal will increase CIPH's exposure in the market place via IVGN's much larger sales force. The products CIPH and BioSepra develop internally address a market of roughly $1 billion. This would be the separations market, which I believe is a hot one (again, per Aebersold's recent comments about more separation steps before MS being the wave of the near future). They'll be producing lab scale chromatography spin columns and sample prep pre-fractionation kits.
Upcoming news flow includes launch of next generation protein chip systems and software, and possible pharma deals for biomarkers, both before year-end. Insiders knew all of the above and sold anyhow, so we're not buying above the low end of their selling range. CIPH is just about there, and is offering one of the few high-throughput proteomics systems that is cheap & easy to use. Plenty of cash to spend on R&D or munches to keep a technological lead, if they're smart. Target range $5 - $5.25 for 1000 shares.
How about that MCLS? Just missed my sell target. A beneficiary of window dressing? Wouldn't that be good timing, if so? PBSC also saw a bit of pachydermal activity, but lost some ground. A bit of positive pachydermal help for DPII, too. But this time CURN didn't bounce back. ITMN also held above targets. Hoping to cash out of MCLS and into some of these in the next couple of days. Anyone want to help me spend about 12K?
Cheers, Tuck |
